angiotensin ii has been researched along with temocapril hydrochloride in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (28.57) | 18.2507 |
| 2000's | 9 (64.29) | 29.6817 |
| 2010's | 1 (7.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brunner, HR; Delacrétaz, E; Nussberger, J; Püchler, K; Robinson, PR; Waeber, B; Wood, AJ | 1 |
| Akitsu, T; Arita, M; Masuyama, Y; Nakamura, C; Nakamura, Y; Nishio, I; Ueno, Y; Wanaka, Y | 1 |
| Araki, H; Futagami, K; Gomita, Y; Kawasaki, H; Takenaga, M | 1 |
| Gao, M; Horimoto, M; Koyama, T; Saito, H; Togashi, H; Xie, Z | 1 |
| Hori, K; Maeda, H; Saito, S; Sato, H; Sato, Y; Takahashi, H | 1 |
| Higaki, J; Matsumoto, K; Moriguchi, A; Morishita, R; Nakagami, H; Nakamura, T; Ogihara, T; Sakonjo, H; Taniyama, Y | 1 |
| Inagaki, K; Iwanaga, Y; Kataoka, K; Kihara, Y; Onozawa, Y; Sasayama, S; Yoneda, T | 1 |
| Fukuda, N; Ikeda, Y; Kanmatsuse, K; Suzuki, R; Tahira, Y; Takagi, H; Teng, J | 1 |
| Iwao, H; Izumi, Y; Kim, S; Nakamura, Y; Omura, T; Takeuchi, K; Yoshida, K; Yoshikawa, J; Yoshiyama, M | 1 |
| Hobara, N; Inaizumi, K; Kawasaki, H; Kurosaki, Y; Nakamura, A | 1 |
| Fukuda, N; Hu, WY; Ikeda, Y; Kanmatsuse, K; Matsumoto, K; Mugishima, H; Suzuki, R; Tahira, Y; Takagi, H | 1 |
| Dong, J; Fujii, S; Furumoto, T; Goto, D; Imagawa, S; Kitabatake, A; Mishima, T; Nakai, Y; Sobel, BE; Zaman, AK | 1 |
| Abe, Y; Kimura, S; Kiyomoto, H; Kobori, H; Kohno, M; Miyata, K; Miyatake, A; Nagai, Y; Nishiyama, A; Ozawa, Y; Shokoji, T; Yao, L; Yukimura, T | 1 |
| Hitomi, H; Ichihara, A; Kobori, H; Kohno, M; Masaki, T; Mori, H; Morimoto, S; Murase, M; Nakano, D; Nishiyama, A; Ohmori, K; Ohnishi, K; Pelisch, N | 1 |
2 trial(s) available for angiotensin ii and temocapril hydrochloride
| Article | Year |
|---|---|
Value of different clinical and biochemical correlates to assess angiotensin converting enzyme inhibition.
Topics: Administration, Oral; Adult; Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Blood Pressure; Dose-Response Relationship, Drug; Double-Blind Method; Drug Evaluation; Humans; Injections, Intravenous; Male; Reproducibility of Results; Tablets; Thiazepines | 1994 |
Effect of temocapril on haemodynamic and humoral responses to exercise in patients with mild essential hypertension.
Topics: Adult; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Exercise; Exercise Test; Female; Hemodynamics; Humans; Hypertension; Male; Middle Aged; Norepinephrine; Renin; Rest; Thiazepines | 1994 |
12 other study(ies) available for angiotensin ii and temocapril hydrochloride
| Article | Year |
|---|---|
Angiotensin inhibits neurotransmission of calcitonin gene-related peptide-containing vasodilator nerves in mesenteric artery of spontaneously hypertensive rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Calcitonin Gene-Related Peptide; Captopril; Mesenteric Arteries; Methoxamine; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Saralasin; Synaptic Transmission; Thiazepines; Vasodilation; Vasomotor System | 1998 |
Rearrangement of the ventricular capillary network in stroke-prone spontaneously hypertensive rats (SHRSP) following a late start of treatment with the angiotensin converting enzyme blocker temocapril.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Capillaries; Coronary Vessels; Heart Rate; Heart Ventricles; Hypertension; Male; Rats; Rats, Inbred SHR; Thiazepines | 1998 |
Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Male; Rats; Regional Blood Flow; Sarcoma, Experimental; Thiazepines | 2000 |
Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Cardiomyopathies; Cells, Cultured; Collagen; Cricetinae; Extracellular Matrix; Fibroblasts; Fibrosis; Hepatocyte Growth Factor; Humans; Imidazoles; In Vitro Techniques; Male; Matrix Metalloproteinase 1; Muscle Fibers, Skeletal; Myocardium; Olmesartan Medoxomil; Rats; Tetrazoles; Thiazepines; Ventricular Remodeling | 2000 |
Differential effects of angiotensin II versus endothelin-1 inhibitions in hypertrophic left ventricular myocardium during transition to heart failure.
Topics: Angiotensin II; Angiotensinogen; Animals; Antihypertensive Agents; Blood Pressure; Bosentan; Disease Progression; Endothelin-1; Endothelins; Gene Expression Regulation; Heart Failure; Heart Ventricles; Hemodynamics; Hypertrophy, Left Ventricular; Male; Organ Size; Peptidyl-Dipeptidase A; Protein Precursors; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; RNA, Messenger; Sulfonamides; Survival Analysis; Thiazepines; Time Factors | 2001 |
Inhibitory effect of a novel angiotensin II type 1 receptor antagonist RNH-6270 on growth of vascular smooth muscle cells from spontaneously hypertensive rats: different anti-proliferative effect to angiotensin-converting enzyme inhibitor.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blotting, Western; Cell Division; Cells, Cultured; Fibroblast Growth Factor 2; Imidazoles; Male; Muscle, Smooth, Vascular; Platelet-Derived Growth Factor; Radioligand Assay; Rats; Rats, Inbred SHR; Rats, Inbred WKY; Receptor, Angiotensin, Type 1; Receptors, Angiotensin; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tetrazoles; Thiazepines; Transforming Growth Factor beta; Transforming Growth Factor beta1 | 2002 |
Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction.
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Atrial Natriuretic Factor; Blotting, Northern; Collagen; Diastole; Drug Therapy, Combination; Echocardiography, Doppler; Imidazoles; Male; Models, Animal; Myocardial Infarction; Myocardium; Natriuretic Peptide, Brain; Olmesartan Medoxomil; Rats; Rats, Wistar; RNA, Messenger; Tetrazoles; Thiazepines; Ventricular Remodeling | 2003 |
Chronic angiotensin II inhibition increases levels of calcitonin gene-related peptide mRNA of the dorsal root ganglia in spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Blood Pressure; Calcitonin Gene-Related Peptide; Ganglia, Spinal; Gene Expression; Hypertension; Imidazoles; Male; Olmesartan Medoxomil; Rats; Rats, Inbred SHR; Rats, Inbred WKY; RNA, Messenger; Tetrazoles; Thiazepines | 2003 |
Human-derived vascular smooth muscle cells produce angiotensin II by changing to the synthetic phenotype.
Topics: Angiotensin I; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Cathepsin D; Cathepsin G; Cathepsins; Cell Division; Cells, Cultured; Fibronectins; Humans; Muscle, Smooth, Vascular; Myocytes, Smooth Muscle; Oligonucleotides, Antisense; Oligopeptides; Phenotype; Serine Endopeptidases; Serine Proteinase Inhibitors; Thiazepines | 2003 |
Salutary effects of attenuation of angiotensin II on coronary perivascular fibrosis associated with insulin resistance and obesity.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Glucose; Collagen Type I; Coronary Disease; Coronary Vessels; Fibrosis; Heart Ventricles; Imidazoles; Insulin; Insulin Resistance; JNK Mitogen-Activated Protein Kinases; Male; Matrix Metalloproteinase 9; Mice; Mice, Obese; Obesity; Olmesartan Medoxomil; Phosphorylation; Plasminogen Activator Inhibitor 1; Tetrazoles; Thiazepines; Transforming Growth Factor beta | 2004 |
Temporary angiotensin II blockade at the prediabetic stage attenuates the development of renal injury in type 2 diabetic rats.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Glucose; Blood Pressure; Body Weight; Collagen; Connective Tissue Growth Factor; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Drug Therapy, Combination; Hydralazine; Imidazoles; Immediate-Early Proteins; Intercellular Signaling Peptides and Proteins; Male; NADPH Oxidases; Olmesartan Medoxomil; Prediabetic State; Rats; Rats, Inbred OLETF; Receptors, Angiotensin; Renin; Tetrazoles; Thiazepines; Thiobarbituric Acid Reactive Substances; Transforming Growth Factor beta | 2005 |
Angiotensin-converting enzyme inhibitor does not suppress renal angiotensin II levels in angiotensin I-infused rats.
Topics: Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Antihypertensive Agents; Blood Pressure; Hypertension; Imidazoles; Kidney; Male; Peptidyl-Dipeptidase A; Rats; Rats, Sprague-Dawley; Renin-Angiotensin System; Tetrazoles; Thiazepines | 2013 |